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ORIGINAL ARTICLE
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ABSTRACT
Background: Differences in cancer survival between the Nordic countries have previously been
reported. The aim of this study was to examine whether these differences in outcome remain, based
on updated information from five national cancer registers.
Materials and methods: The data used for the analysis was from the NORDCAN database focusing
on nine common cancers diagnosed 1990–2016 in Denmark, Finland, Iceland, Norway and Sweden
with maximum follow-up through 2017. Relative survival (RS) was estimated at 1 and 5 years using
flexible parametric RS models, and percentage point differences between the earliest and latest years
available were calculated.
Results: A consistent improvement in both 1- and 5-year RS was found for most studied sites across
all countries. Previously observed differences between the countries have been attenuated. The
improvements were particularly pronounced in Denmark that now has cancer survival similar to the
other Nordic countries.
Conclusion: The reasons for the observed improvements in cancer survival are likely multifactorial,
including earlier diagnosis, improved treatment options, implementation of national cancer plans, uni-
form national cancer care guidelines and standardized patient pathways. The previous survival disad-
vantage in Denmark is no longer present for most sites. Continuous monitoring of cancer survival is of
importance to assess the impact of changes in policies and the effectiveness of health care systems.
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Marked differences in cancer incidence and survival between
countries and jurisdictions have been documented in several
reports, as well as differences in temporal trends across
countries and calendar time [1–4]. A series of 13 articles pub-
lished in 2010 comparing time trends in cancer incidence
and outcomes in the five Nordic countries 1964–2003
(https://www.ancr.nu/cancer-data/cancer-survival/acta-onco-
logica-2010) confirmed earlier findings of both similarities
and differences in cancer survival, with notable poorer out-
comes observed in Denmark. At that time, one conclusion
was that cancer plans initiated in Denmark in 2000 and in
Norway in 1997, appeared to not yet have had an impact
on cancer incidence, mortality or survival [5]. A more recent
study which compared cancer survival in Europe
1999–2007, EUROCARE-5, also reported a survival disadvan-
tage in Danish patients [3].
With more than 10 years of additional data available, it is
now possible to investigate if concerted national efforts to
improve early detection and quality of cancer care have had
detectable effects, and if differences in cancer survival
between the Nordic countries still persist. Since the 2010
comprehensive Nordic comparison, efforts to improve cancer
care have been made in each Nordic country. These efforts
include implementing and updating national cancer plans
and guidelines, changes in screening programs, centralization
of cancer treatment, accelerated cancer patient pathways
and improved access to new cancer therapies.
This study utilizes data on nine common cancers diag-
nosed between 1990 and 2016 from the NORDCAN database
[6], which is a collaboration between the cancer registries of
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Denmark, Finland, Iceland, Norway and Sweden [7]. Summary
incidence, mortality and survival figures from NORDCAN are
published online [8]. The aim of this Nordic collaborative
study is three-fold. First, to study possible changes in both
short and long-term survival over this time period by esti-
mating overall and conditional cancer survival. Second, to
investigate whether previously observed differences in can-
cer survival between the Nordic countries remain. Third, to
put these results into context, we also present trends in can-
cer incidence and mortality.
Methods
Data
We obtained individual-level data for nine common cancer
from Denmark, Finland, Iceland, Norway and Sweden from
the NORDCAN database, which includes information from
the national cancer registries in each country [6–8]. All indi-
viduals diagnosed with the following cancers between 1990
and 2016 were included: primary cancers of the colon
(including appendix, International Classification of Diseases
version 10 [ICD10]: C18), rectum (C19–C20), lung and trachea
(C33–C34), malignant melanoma of skin (C43), kidney (C64),
breast (C50), uterus (corpus uteri, C54), ovary (including fallo-
pian tubes and uterine ligaments, C56–C57.4) and prostate
(C61). Follow-up for death and emigration was to the end of
2017 for all countries, except for Finland where follow-up
ended in 2016. Emigration information was unavailable
for Iceland.
We excluded cases diagnosed only on the basis of a
death certificate (DCO) or through incidental autopsy find-
ings. We also excluded childhood cancers (patients aged
<18 years at diagnosis), breast cancer in men and subse-
quent primary tumors at the same site in the same patient
(Supplementary Table 1).
Population-based expected mortality rates in each coun-
try, stratified by age, sex and calendar year were obtained
from each country’s national statistics office.
Statistical analysis
We estimated marginal relative survival (RS) to quantify sur-
vival in the absence of death from other causes. We present
1-year and 5-year RS, and 5-year RS conditional on survival
to 1-year post-diagnosis for women and men, across coun-
tries and calendar time. We adopted a modeling approach to
estimate RS using flexible parametric RS models fitting separ-
ate models to each cancer site for each country. The models
incorporated age at diagnosis, calendar year and sex (for
relevant sites). After fitting the model, age-standardized esti-
mates of RS were obtained using regression standardization
stratified by calendar year and sex [9]. We used an adapted
version of the International Cancer Survival Standard 1
(ICSS1) age-standard weights for all cancer sites by 10-year
age groups, except for melanoma where the adapted ICSS2
weights were used (Supplementary Table 2).
Flexible parametric RS models use restricted cubic splines
to model the baseline excess hazard over time since diagno-
sis [10,11]. The models incorporate the expected mortality
rates for each country. In the analyses, 5 degrees of freedom
(df) were used to model the log cumulative baseline excess
hazard with sex as a binary covariate. Age and calendar year
at diagnosis were included as continuous variables allowing
for non-linear effects by using restricted cubic splines with 3
df. Two-way interactions between age and calendar year, age
and sex, and calendar year and sex were included. The pro-
portional excess hazards assumption was relaxed by incorpo-
rating time-dependent effects for calendar year, age, sex,
and their interaction terms (three-way interactions), with 3 df
for each time-dependent effect.
Due to the small population size, simpler models were
used for Iceland. These excluded the three-way interactions
and used 2 df for time-dependent effects. For cancers of the
uterus, ovary and melanoma in Iceland, there were few can-
cer cases and/or deaths. For that reason a modeling
approach was not adopted and estimates were obtained
using the non-parametric Pohar Perme approach in 5-year
groups of calendar year at diagnosis [12], incorporating rela-
tive weights [13]. To improve model stability for the very
young and elderly, 96% of the age distribution was modeled
continuously while individuals outside the 2nd and 98th per-
centile of age had their age reassigned to those percentile
limits and were assumed to have the same RS (i.e. winsoriz-
ing) [14]. As a validation of our models, we compared the
parametric estimates to Pohar Perme estimates and found
them to be in good agreement.
Absolute survival differences, as measured by percentage
point (pp) differences in 5-year RS between 1990 and 2010,
and 1-year RS between 1990 and 2015, were estimated with
95% confidence intervals (CI) from the models. The corre-
sponding differences for cancers of the uterus, ovary and
melanoma in Iceland were calculated from the latest and
earliest non-parametric estimates.
As improvements in 5-year survival often reflect improve-
ments in early survival (e.g. within a year of diagnosis), the
5-year RS conditional on surviving 1 year captures the
1–5 year survival experience of the patients. This is important
in order to disentangle the early and later survival improve-
ments over the first 5 years since diagnosis.
In addition to modeling trends over time, a period ana-
lysis model was used to obtain up-to-date estimates where
only follow-up time during a period window was included in
the analysis. The period window was 2013–2017 for
Denmark, Norway, Sweden, 2012–2017 for Iceland and
2013–2016 for Finland. These models were essentially the
same as above, without the need to incorporate calendar
year. For melanoma in Denmark and kidney cancer in
Norway, the models were simplified by using 2 df for time-
dependent effects due to convergence issues. Non-paramet-
ric estimates were calculated for cancers of the uterus, ovary
and melanoma in Iceland.
Incidence and mortality rates were estimated using 3-year
diagnoses windows. Rates were age standardized using
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the Nordic population distribution in the year 2000
(Supplementary Table 3).
All the analyses were performed in Stata/IC 16.0
(StataCorp. 2019. Stata Statistical Software: Release 16.
College Station, TX: StataCorp LLC). The commands stpm2
and standsurv were used for obtaining parametric esti-
mates, and strs for non-parametric estimates [15,16].
Ethical approval for this study was granted by the
Swedish Ethical Review Authority (ethical approval 2017/641-
31/1, amendment 2019-01913) and study permission from
the National Institute of Health and Welfare in Finland
(approval THL/870/5.05.00/2014, amendment 2019).
Results
In total, the cohorts from the five Nordic countries included
1,032,846 cancers in women and 1,006,836 cancers in men
for nine tumor sites diagnosed between 1990 and 2016. The
number of cases and exclusions by sex, site and country are
presented in Supplementary Table 1. Breast, lung and colon
cancer were the three most common sites among women,
while prostate, lung and colon cancer were the most com-
mon sites among men.
Colon cancer
Period estimates of 5-year RS for colon cancer ranged from
62% (Iceland) to 69% (Norway) in women and from 63%
(Sweden) to 67% (Denmark) in men (Table 1). Survival
improved over the study period in all Nordic countries for
both women (Figure 1(a)) and men (Figure 1(b)). The lower
1- and 5-year RS in Denmark in the early 1990s improved
over time and was in line with the other Nordic countries at
the end of the study period. The change in 5-year RS
between 1990 and 2010 was þ16 pp in Danish women and
þ17 pp in men (Table 2). There was also an improvement in
5-year RS conditional on survival 1-year in both women and
men (Figure 2). The incidence of colon cancer increased in
both sexes over the study period, while there was a slight
decrease in mortality (Supplementary Figure 1a and 1b).
Rectal cancer
For rectal cancer, the period estimates of 5-year RS ranged
from 68% (Sweden) to 78% (Iceland) in women and between
65% (Finland, Sweden) and 69% (Denmark, Norway) in men
(Table 1). Survival improved in all Nordic countries for both
women (Figure 1(a)) and men (Figure 1(b)), with particularly
pronounced improvements in women in Denmark and
Iceland. The change in 5-year RS was þ28 pp in Icelandic
women and þ22 pp in both Danish women and men from
1990 to 2010 (Table 2). There was also an improvement in 5-
year RS conditional on surviving 1 year in both women and
men (Figure 2). During the period under study, the rectal
cancer incidence remained constant in both sexes, while
mortality decreased (Supplementary Figure 1a and 1b).
Lung cancer
Among individuals with lung cancer, the period estimates of
5-year RS ranged from 19% (Finland) to 26% (Iceland,
Norway) in women and between 13% (Finland) and 20%
(Iceland) in men (Table 1). One-year RS improved markedly
over the study period in all countries for both women
(Figure 1(a)) and men (Figure 1(b)), in particular in the 2000s.
The change in 1-year RS from 1990 to 2015 was þ30 pp in
Danish, þ25 pp in Swedish and þ22 pp in Norwegian
women, while in men the corresponding numbers were þ23
pp, þ20 pp and þ18 pp (Table 2). Improvements in 1-year
RS were less pronounced in Finland (þ12 pp in women and
þ5 pp in men) and Iceland (þ19 pp in women and þ12 pp
in men) (Table 2). In all Nordic countries, improvements in 1-
year RS were more marked than improvement in 5-year RS.
There was, however, an improvement in 5-year RS condi-
tional on survival 1 year in both women and men, especially
after 2005 (Figure 2). Lung cancer incidence and mortality in
Table 1. Period estimates of 5-year relative survival with 95% confidence intervals, by sex, site and country in the latest available 5-year period, the NORDCAN
survival studies.
Site ICD-10 Denmark Finland Iceland Norway Sweden
Women
Colon C18 68 (67–69) 68 (66–70) 62 (57–68) 69 (68–71) 65 (64–67)
Rectum C19–C20 71 (70–73) 69 (67–72) 78 (70–88) 71 (69–73) 68 (66–69)
Lung C33–C34 23 (22–24) 19 (17–20) 26 (22–31) 26 (25–27) 24 (23–25)
Melanoma C43 95 (94–96) 94 (93–95) 97 (87–99)a 93 (92–94) 94 (94–95)
Kidney C64 69 (66–72) 68 (66–71) 73 (64–82) 75 (72–78) 75 (73–78)
Breast C50 87 (87–88) 90 (90–91) 87 (84–90) 89 (88–90) 90 (89–90)
Uterus C54 82 (81–84) 84 (82–85) 84 (73–91)a 84 (83–86) 84 (83–85)
Ovary C56–C57.4 42 (40–44) 44 (42–46) 46 (35–56)a 47 (45–50) 51 (49–52)
Men
Colon C18 67 (65–68) 66 (64–68) 66 (60–72) 65 (64–67) 63 (62–65)
Rectum C19–C20 69 (67–71) 65 (63–67) 67 (59–76) 69 (68–71) 65 (64–66)
Lung C33–C34 17 (16–18) 13 (12–14) 20 (17–25) 19 (18–20) 19 (18–20)
Melanoma C43 91 (90–92) 87 (86–89) 86 (76–91)a 87 (86–89) 91 (90–92)
Kidney C64 67 (65–69) 65 (62–67) 65 (58–73) 72 (70–74) 74 (72–76)
Prostate C61 87 (86–87) 94 (93–95) 89 (86–91) 93 (92–94) 91 (91–92)
Follow-up window for Denmark, Norway and Sweden: 2013–2017; Finland: 2013–2016; Iceland: 2012–2017.
aAge-standardized Pohar Perme estimates over 5-year intervals of calendar year.
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women increased over time while decreasing in men
(Supplementary Figure 1a and 1b).
Melanoma of skin
For melanoma, the period estimates of 5-year RS ranged
from 93% (Norway) to 97% (Iceland) in women and from
86% (Iceland) to 91% (Denmark, Sweden) in men (Table 1).
Despite high survival in the 1990s, further improvements
were observed in both men and women in all countries
(Figure 1(a,b)). There was also improvement in 5-year RS con-
ditional on surviving 1 year (Figure 2). There was a rapid
increase in the melanoma incidence in both sexes in all
countries (except Iceland where incidence has decreased in
the later years). The mortality remained fairly stable with the
Figure 1. (a) Trends over time in 1- and 5-year relative survival 1990–2016, women, the NORDCAN survival studies. Age-standardized Pohar Perme estimates over
5-year intervals of calendar year presented for melanoma, ovarian and uterine cancer in Iceland. Crosses mark the center of each interval. (b) Trends over time in
1- and 5-year relative survival 1990–2016, men, the NORDCAN survival studies. Age-standardized Pohar Perme estimates over 5-year intervals of calendar year pre-
sented for melanoma in Iceland. Crosses mark the center of each interval.
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exception of Norway, where there was a slight increase
(Supplementary Figure 1a and 1b).
Kidney cancer
For kidney cancer, the period estimates of 5-year RS ranged
from 68% (Finland) to 75% (Norway, Sweden) in women and
between 65% (Finland, Iceland) and 74% (Sweden) in men
(Table 1). Survival improved in all Nordic countries for both
women (Figure 1(a)) and men (Figure 1(b)), in particular for
Denmark, but less so for Finland. The change in 5-year RS
from 1990 to 2010 was just over 20–23 pp in both women
and men in all countries except in Finland where the change
was þ13 pp (women) and þ12 pp (men) (Table 2). The
improvement in 5-year RS conditional on surviving 1 year
was the largest in Denmark for both women and men
(Figure 2). The incidence of kidney cancer was mainly stable
over the study period and countries in women, while the
incidence increased in Danish and Norwegian men
(Supplementary Figure 1a and 1b). Mortality decreased
somewhat in all countries.
Breast cancer
For breast cancer, the period estimates of 5-year RS esti-
mates ranged from 87% (Denmark, Iceland) to 90% (Finland,
Sweden) (Table 1). During the study period, both 1- and 5-
year RS improved in all countries (Figure 1(a)), in particular in
Denmark with aþ 16 pp change in 5-year RS from 1990 to
2010 (Table 2). Improvements were also observed in 5-year
RS conditional on surviving 1 year (Figure 2). Breast cancer
incidence increased in all countries, with the highest inci-
dence in Denmark and lowest in Norway, while mortality
decreased (Supplementary Figure 1a).
Uterine cancer
For uterine cancer, the period estimates of 5-year RS esti-
mates ranged from 82% (Denmark) to 84% (Finland, Iceland,
Norway, Sweden) (Table 1). In all countries, there were only
small improvements in both 1- and 5-year RS over the study
period (Figure 1(a)), with the largest increase in Iceland. The
change in 5-year RS ranged from þ5 to þ19 pp across
Figure 1. (Continued).
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countries from 1990 to 2010 (Table 2). The incidence trend
of uterine cancer varied between countries, with an increase
in Norway and only minor increases in the other countries
(Supplementary Figure 1a). While mortality remained stable
in Finland, Sweden and Iceland, there was evidence of a
decrease in Denmark and Norway (Supplementary Figure 1a).
Ovarian cancer
For ovarian cancer, the period estimates of 5-year RS
estimates ranged from 42% (Denmark) to 51% (Sweden)
(Table 1). Over the study period, both 1- and 5-year RS
improved in all countries (Figure 1(a)). The change in 1-year
RS from 1990 to 2015 was þ7 pp in Iceland and ranged
from þ14 pp to þ20 pp in the other countries (Table 2).
The change in 5-year RS varied between þ8 pp (Iceland) and
þ15 pp (Finland) (Table 2). The improvements in 5-year
RS conditional on surviving 1 year were less pronounced
(Figure 2). The incidence and mortality of ovarian cancer
decreased in all Nordic countries (Supplementary Figure 1a).
Prostate cancer
For prostate cancer, the period estimates of 5-year RS esti-
mates ranged from 87% (Denmark) to 94% (Finland) (Table
1). Both 1- and 5-year RS improved in all Nordic countries
(Figure 1(b)), in particular in Denmark where the
improvement was most pronounced for men diagnosed
between 2000 and 2010. The change in 1- and 5-year RS was
þ15 pp and þ51 pp, respectively, in Danish men from 1990
to 2015/2010 (Table 2). Similar patterns of improvement
were also observed in 5-year RS conditional on surviving 1
year (Figure 2). Prostate cancer incidence increased in all
countries, although the increase in Denmark occurred later.
Prostate cancer mortality decreased across all countries
(Supplementary Figure 1b).
Point estimates of 1- and 5-year RS for every 5th calendar
year, with 95% confidence intervals, are presented in
Supplementary Tables 4 and 5. The corresponding estimates
of 5-year RS conditional on surviving 1 year after diagnosis
are presented in Supplementary Table 6.
Discussion
Including more than 2 million men and women diagnosed
with cancer, we found general and consistent improvements
in both short- and long-term cancer survival across nine
major cancer sites in the Nordic countries between 1990 and
2017. The previously observed survival disadvantage in
Denmark up until 2006 [5] is no longer present for most
sites, with improvements in both 1-year and 5-year survival.
Although the survival trends in general are consistent over
the Nordic countries, an exception is in Finland where lung
and kidney cancer survival has improved less over time.
Table 2. Percentage point change in 1- and 5-year relative survival since 1990 with 95% confidence intervals, by sex, site and coun-
try, the NORDCAN survival studies.
Site Denmark Finland Iceland Norway Sweden
Change in 1-year relative survival between 1990 and 2015
Women
Colon 16 (15 to 18) 12 (10 to 14) 7 (2 to 15) 13 (11 to 14) 10 (8 to 11)
Rectum 14 (12 to 17) 9 (6 to 12) 11 (0 to 23) 9 (7 to 11) 8 (6 to 10)
Lung 30 (29 to 32) 12 (9 to 14) 19 (11 to 26) 22 (19 to 24) 25 (23 to 27)
Melanoma 3 (2 to 4) 3 (1 to 4) 4 (3 to 11)a 2 (1 to 2) 1 (1 to 2)
Kidney 28 (25 to 32) 12 (9 to 16) 27 (11 to 43) 18 (15 to 22) 20 (18 to 23)
Breast 5 (5 to 6) 3 (2 to 4) 5 (1 to 9) 4 (3 to 5) 3 (2 to 3)
Uterus 5 (3 to 7) 3 (1 to 5) 6 (-5 to 18)a 8 (6 to 10) 3 (2 to 4)
Ovary 18 (15 to 21) 14 (11 to 17) 6 (-14 to 25)a 16 (13 to 19) 20 (18 to 22)
Men
Colon 20 (18 to 22) 12 (9 to 14) 8 (0 to 17) 14 (12 to 16) 12 (10 to 13)
Rectum 17 (15 to 19) 10 (8 to 13) 1 (12 to 13) 12 (10 to 14) 10 (8 to 11)
Lung 23 (22 to 24) 5 (3 to 7) 12 (5 to 19) 18 (16 to 20) 20 (18 to 21)
Melanoma 5 (4 to 7) 2 (0 to 4) 5 (19 to 10)a 4 (3 to 6) 3 (2 to 3)
Kidney 27 (23 to 30) 12 (9 to 16) 17 (4 to 30) 19 (16 to 23) 22 (19 to 25)
Prostate 15 (13 to 17) 10 (9 to 12) 6 (2 to 11) 9 (7 to 10) 8 (7 to 9)
Change in 5-year relative survival between 1990 and 2010
Women
Colon 16 (13 to 18) 13 (10 to 16) 9 (2 to 20) 13 (11 to 15) 13 (11 to 15)
Rectum 22 (19 to 25) 18 (14 to 21) 28 (12 to 44) 15 (12 to 18) 12 (9 to 14)
Lung 11 (10 to 12) 5 (3 to 7) 12 (7 to 16) 10 (8 to 11) 10 (8 to 11)
Melanoma 7 (5 to 9) 7 (4 to 10) 8 (-5 to 21)b 2 (0 to 4) 3 (1 to 4)
Kidney 23 (18 to 27) 13 (9 to 16) 23 (6 to 40) 22 (17 to 26) 21 (18 to 25)
Breast 16 (14 to 17) 11 (9 to 12) 13 (6 to 20) 13 (12 to 15) 8 (7 to 9)
Uterus 5 (2 to 7) 5 (3 to 8) 19 (1 to 37)b 10 (7 to 13) 7 (5 to 9)
Ovary 13 (10 to 15) 15 (12 to 18) 8 (8 to 24)b 13 (10 to 15) 11 (9 to 13)
Men
Colon 17 (15 to 20) 13 (10 to 17) 9 (3 to 21) 14 (12 to 17) 12 (10 to 14)
Rectum 22 (20 to 25) 17 (13 to 20) 20 (1 to 39) 18 (15 to 21) 14 (11 to 16)
Lung 7 (6 to 8) 2 (1 to 4) 7 (2 to 12) 7 (6 to 8) 7 (6 to 8)
Melanoma 14 (11 to 17) 9 (5 to 12) 16 (7 to 39)b 5 (3 to 8) 5 (3 to 7)
Kidney 23 (19 to 27) 12 (8 to 16) 21 (7 to 34) 20 (16 to 24) 22 (19 to 25)
Prostate 51 (49 to 53) 41 (39 to 44) 21 (12 to 29) 36 (34 to 39) 31 (30 to 33)
aBased on age-standardized Pohar Perme estimates from diagnosis years 1990–1994 and 2015–2016.
bBased on age-standardized Pohar Perme estimates from diagnosis years 1990–1994 and 2010–2014.
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Reasons for the observed improvement in cancer survival are
likely to be multifactorial involving major changes over the last
30 years not only in diagnostic and treatment options, but also
in policies and resource allocation. Similar improvements have
also been seen in countries outside the Nordic region [1,2].
From the early 2000s, national cancer plans or strategies were
implemented in the Nordic countries aiming to improve early
detection and delivery of cancer care, starting in Denmark
(2000), in Norway (2006), Sweden (2011) and very recently in
Iceland (2019). Similar efforts have been undertaken in Finland.
The national cancer plans have been developed with a focus on
the patient perspective and include components such as
Figure 2. Trends in 5-year relative survival conditional on surviving 1 year, 1990–2012, the NORDCAN survival studies. Age-standardized Pohar Perme estimates
over 5-year intervals of calendar year presented for melanoma, uterine and ovarian cancer in Iceland. Crosses mark the center of each interval.
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uniform national cancer care guidelines, contact nurses, multidis-
ciplinary treatment decisions, individualized management plans,
centralization of treatment to fewer central, structured care proc-
esses and standardized pathways aiming to reduce wait-
ing times.
Other recent changes include the introduction of new diag-
nostic methods allowing for targeted treatments, new onco-
logical treatments and refined surgical techniques. Novel
diagnostic tools have led not only to more precise tumor
characterization and staging, but also to an increased inci-
dence of early stage tumors and incidental findings [17].
There have also been efforts to improve early detection by
public campaigns to increase awareness of signs and symp-
toms of cancer, implementation of organized colorectal cancer
screening and increased participation in existing screening
programs for breast cancer (Supplementary Table 7).
The improvements in cancer survival were particularly
pronounced in Denmark that now has a cancer survival simi-
lar to the other Nordic countries. Denmark was the first
Nordic country to launch a national cancer plan in 2000 fol-
lowed by several updates, including a 2007 policy decision
to designate cancer as an acute life-threatening disease with
a focus on accelerated cancer patient pathways to reduce
waiting times. Denmark was early in implementing acceler-
ated cancer pathways 2007–2009 [18]. Changes in Denmark
have also included structural reforms with healthcare pro-
vided by five administrative healthcare regions from 2007
and marked increases in health care expenditures including
earmarked investments in resources for cancer care, for
example computed tomography (CT) and radiation therapy.
It is also possible that changes over time in comorbidity
burden and life-style factors such as smoking could have
played a role for the marked improvements observed in
Denmark. Smoking is associated with a higher comorbidity
burden, which in turn may affect cancer treatment options
and survival. Smoking prevalence has historically been high
in Denmark, but has decreased markedly over time and is
since the end of 1990s more similar to the other Nordic
countries [5].
Although there have been general improvements in sur-
vival across sites, there are some exceptions. It is unclear
why the improvement in survival for lung and kidney cancer
was less pronounced in Finland than in the other countries.
The observed differences in both 1-year and 5-year condi-
tional survival could reflect varying diagnostic pathways and
routines. There are observed differences in treatment proto-
cols and patient pathways, implementation and frequency of
updates of lung cancer related national guidelines and smok-
ing cessation advice between the Nordic countries [19].
However, it is important to investigate further why improve-
ments in survival have been less pronounced in Finland and
if there are for example differences in lung cancer subtypes
between countries.
The substantial improvement observed for prostate cancer
survival is likely to be partly explained by an increased use of
prostate-specific antigen (PSA) testing (which is also reflected
in a corresponding sharp increase in prostate cancer inci-
dence), in addition to more men receiving treatment with
curative intent. Although routine PSA testing now is discour-
aged in all Nordic countries, testing of asymptomatic men is
still performed at a varying degree at patients’ request.
The incidence of melanoma of the skin has increased rap-
idly in both men and women in all Nordic countries with the
exception of Iceland was the incidence has decreased, pos-
sibly as an effect of awareness campaigns and regulations
for use of sunbeds introduced in 2003 [20]. There has been
no corresponding increase in melanoma mortality, suggest-
ing that the increase in incidence reflects the detection of
early stage melanomas.
The Nordic countries have a population of over 27 million
with low out-of-pocket-cost care available to all residents via
similar tax-funded national healthcare systems. The
NORDCAN database collaboration has facilitated data collec-
tion, reporting and coding practices of cancer cases. The
NORDCAN database is population-based, mature and essen-
tially complete including more than 2 million cancer patients
and represents an important resource for cancer compari-
sons. Complete follow-up for death and migration is pro-
vided by record linkages to the Total Population Registers in
each country except Iceland where migration information is
unavailable. Also, traceback systems to supplement informa-
tion on the time of diagnosis on cancers with only death cer-
tificate notifications to the cancer registry is undertaken in
all Nordic countries except Sweden [7]. For many cancer
sites, non-inclusion of death certificate initiated cases (DCI)
will lead to a slight overestimation of survival, whereas
including these cases will slightly underestimate survival [21].
Taken together, these biases could impact the comparisons
of survival between countries, in particular for cancer sites
with short survival time, such as lung cancer, or in the eld-
erly. Limitations of our study also include the low numbers
for some cancer sites, particularly for Iceland, and 1 year less
follow-up in Finland.
Conclusions
There have been general improvements in cancer survival
across nine major cancer sites in the Nordic countries.
Although some differences in cancer survival remain, previ-
ously observed marked differences between countries have
been attenuated over time. Of special note is that the previ-
ous survival disadvantage in Denmark is no longer present
for most sites. The reasons for these improvements are multi-
factorial, including concerted efforts to improve cancer care
by means of national cancer plans, earlier diagnosis and
improvements in treatment. Cancer registration is essential
to continue monitoring cancer survival and assess the impact
of changes in policies and quality of care. In addition, data
from cancer registers enable quantification and understand-
ing of national as well as international trends and differences
in cancer survival, incidence, and mortality. With the increas-
ing availability and completeness of treatment and disease-
specific information (e.g. stage and histological subtype),
more detailed comparisons will be possible to further
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